The estimated Net Worth of Kevin Lee is at least $17.4 Milhão dollars as of 3 July 2024. Dr Lee owns over 3,194 units of Bicycle Therapeutics plc stock worth over $10,354,689 and over the last 5 years he sold BCYC stock worth over $5,889,951. In addition, he makes $1,156,784 as CEO & Exec. Director at Bicycle Therapeutics plc.
Dr has made over 21 trades of the Bicycle Therapeutics plc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,194 units of BCYC stock worth $62,730 on 3 July 2024.
The largest trade he's ever made was exercising 58,919 units of Bicycle Therapeutics plc stock on 28 April 2021 worth over $824,866. On average, Dr trades about 11,020 units every 51 days since 2019. As of 3 July 2024 he still owns at least 384,076 units of Bicycle Therapeutics plc stock.
You can see the complete history of Dr Lee stock trades at the bottom of the page.
Dr. Kevin Lee M.B.A., Ph.D. is the CEO & Exec. Director at Bicycle Therapeutics plc.
As the CEO & Exec. Director of Bicycle Therapeutics plc, the total compensation of Dr D at Bicycle Therapeutics plc is $1,156,784. There are no executives at Bicycle Therapeutics plc getting paid more.
Dr D is 52, he's been the CEO & Exec. Director of Bicycle Therapeutics plc since . There are 5 older and 6 younger executives at Bicycle Therapeutics plc. The oldest executive at Bicycle Therapeutics plc is Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, 70, who is the Co-Founder, Non-Exec. Director & Member of Scientific Advisory Board.
Kevin's mailing address filed with the SEC is C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS.
Over the last 5 years, insiders at Bicycle Therapeutics plc have traded over $10,024,476 worth of Bicycle Therapeutics plc stock and bought 3,275,775 units worth $45,860,850 . The most active insiders traders include Plc Gsk, Bros. Advisors Lp667, L.P.B..., eBioventures Ltd Novartis Ag.... On average, Bicycle Therapeutics plc executives and independent directors trade stock every 19 days with the average trade being worth of $1,155,236. The most recent stock trade was executed by Michael Charles Ferguson Ha... on 3 July 2024, trading 246 units of BCYC stock currently worth $4,831.
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Bicycle Therapeutics plc executives and other stock owners filed with the SEC include: